Evidence map›Paper›PMID 22245894›Full record

ArticleJournal of hepatology2012

Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.

Masafumi Shimoda, Yoshito Tomimaru, Kevin P Charpentier, Howard Safran, Rolf I Carlson, Jack Wands

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Aspartate β-hydroxylase as a target for cancer therapy.Journal of experimental & clinical cancer research : CR · 2020
    Review
  16. Article
  17. Frontiers in cell and developmental biology · 2020
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Masafumi ShimodaLiver Research Center, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Yoshito TomimaruLiver Research Center, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Kevin P CharpentierThe Department of Surgery, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Howard SafranThe Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Rolf I CarlsonLiver Research Center, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Jack WandsLiver Research Center, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA; The Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: jack_wands_md@brown.edu.
Brown University · USRhode Island Hospital · US

Funding

Biomarker for Hepatocellular CarcinomaR01CA123544 · NCI · RHODE ISLAND HOSPITAL · PI WANDS, JACK R · 2007 to 2011
$1.2M
NCI NIH HHS CA-123544NCI NIH HHS R01 CA123544
6 · The paper itself

Abstract

BACKGROUND &

aimsHepatocellular carcinoma (HCC) has a poor survival rate due to recurrent intrahepatic metastases and lack of effective adjuvant therapy. Aspartate-β-hydroxylase (ASPH) is an attractive cellular target since it is a highly conserved transmembrane protein overexpressed in both murine and human HCC tumors, and promotes a malignant phenotype as characterized by enhanced tumor cell migration and invasion.

methodsDendritic cells (DCs), expanded and isolated from the spleen, were incubated with a cytokine cocktail to optimize IL-12 secretion and co-stimulatory molecule expression, then subsequently loaded with ASPH protein for immunization. Mice were injected with syngeneic BNL HCC tumor cells followed by subcutaneous inoculation with 5-10×10(5) ASPH loaded DCs using a prophylactic and therapeutic experimental approach. Tumor infiltrating lymphocytes (TILs) were characterized, and their role in producing anti-tumor effects determined. The immunogenicity of ASPH protein with respect to activating antigen specific CD4+ T cells derived from human peripheral blood mononuclear cells (PBMCs) was also explored.

resultsWe found that immunotherapy with ASPH-loaded DCs suppressed and delayed established HCC and tumor growth when administered prophylactically. Ex-vivo re-stimulation experiments and in vivo depletion studies demonstrated that both CD4+ and CD8+ cells contributed to anti-tumor effects. Using PBMCs derived from healthy volunteers and HCC patients, we showed that ASPH stimulation led to significant development of antigen-specific CD4+ T-cells.

conclusionsImmunization with ASPH-loaded DCs has substantial anti-tumor effects which could reduce the risk of HCC recurrence.

Indexed as

Disease ProgressionAnimalsCalcium-Binding ProteinsCarcinoma, HepatocellularCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineDendritic CellsDisease Models, AnimalFemaleHumansImmunotherapyLeukocytes, MononuclearLiver NeoplasmsMembrane ProteinsMiceAsph protein, mouseCalcium-Binding ProteinsMembrane ProteinsMixed Function OxygenasesMuscle Proteins

Identifiers

PMID22245894
PMCPMC3328647
OpenAlexW2108043715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.